GlassScriptPhysician profile
Shawn Couture
NPI 1548464175
$3,662.56
in general payments reported to CMS, 2019-2025
29 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $268 · 2021: $780 · 2022: $906 · 2023: $513 · 2024: $458 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.70 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $607.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $315.01 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $296.20 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $272.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $226.29 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $176.67 | 2019-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $119.96 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $111.80 | 2019-2022 | |
| Amgen INC. | $109.41 | 2020-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $93.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $90.62 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $74.53 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.12 | 2022 | |
| Dexcom, INC. | $60.50 | 2021-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.81 | 2021-2025 | Xifaxan |
| Allergan, INC. | $45.85 | 2020 | |
| Sanofi-Aventis U.S. LLC | $40.81 | 2020-2022 | |
| Astellas Pharma US INC | $35.00 | 2023 | Veozah |
| Covis Pharma Gmbh | $34.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.80 | 2021 | |
| Biosense Webster, INC. | $20.74 | 2021 | |
| Nevro Corp. | $20.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.64 | 2023 | Seglentis, Livalo |
| Exact Sciences Corporation | $18.92 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $18.35 | 2023 | Yupelri |
| Hologic Sales and Service, LLC | $18.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.79 | 2023 | Farxiga |
| Qiagen, LLC | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Couture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.